Arcturus Therapeutics Stock (NASDAQ: ARCT)

Arcturus Therapeutics

ARCTURUS THERAPEUTICS HOLDIN

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

10 Alarming Facts About FLiRT And LB.1, The New COVID Variants Reshaping The Pandemic

Biotech

Equities

Large Cap

News

Health Care

General

ARCT

CSLLY

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer&#39;s Comirnaty in a Phase 3 study, persisting for one year and at a lower dose.

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer&#39;s Comirnaty Shot, Even At Lower Doses

Earnings

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

Arcturus Therapeutics (NASDAQ: ARCT) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.

Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

Earnings Beats

Penny Stocks

ANTX

FULC

ILMN

AN2 Therapeutics (NASDAQ: ANTX), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.

AN2 Therapeutics Plunges 66% in a Month: Here&#39;s Why

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

Press Releases

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Absci

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Astria Therapeutics

aTyr Pharma

Aura Biosciences

Benitec Biopharma

Candel Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Heron Therapeutics

Humacyte

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Solid Biosciences

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

2seventy bio

Upstream Bio

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Arcturus Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga